Hildegard Keppeler

Otfried Mueller Str. 10
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Characterizing the impact of MLL fusion variants and fusion partners on leukemia plasticity using a human CRISPR-engineered MLL-rearranged leukemia model.

Characterizing the impact of MLL fusion variants and fusion partners on leukemia plasticity using a human CRISPR-engineered MLL-rearranged leukemia model.

Journal: Neoplasia (New York, N.Y.)

Published: February 25, 2026

Laminin receptor characterization in acute myeloid leukemia: integrin α7β1 defines leukemic cells with migratory potential.

Laminin receptor characterization in acute myeloid leukemia: integrin α7β1 defines leukemic cells with migratory potential.

Journal: Experimental hematology

Published: August 04, 2025

Only Infant MLL-Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib.

Only Infant MLL-Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib.

Journal: International journal of molecular sciences

Published: September 29, 2024

CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity.

CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity.

Journal: Cytotherapy

Published: March 15, 2024

PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.

PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.

Journal: Journal for immunotherapy of cancer

Published: December 21, 2023

Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype.

Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype.

Journal: Frontiers in oncology

Published: November 06, 2023

Uncovering NOTCH1 as a Promising Target in the Treatment of MLL-Rearranged Leukemia.

Uncovering NOTCH1 as a Promising Target in the Treatment of MLL-Rearranged Leukemia.

Journal: International journal of molecular sciences

Published: August 29, 2023

The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia.

The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia.

Journal: Oncogene

Published: June 08, 2023

Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.

Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.

Journal: Neoplasia (New York, N.Y.)

Published: February 06, 2023

Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation.

Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: March 02, 2022

iNKT cells can effectively inhibit IL-6 production by B cells in systemic sclerosis.

iNKT cells can effectively inhibit IL-6 production by B cells in systemic sclerosis.

Journal: Cytotherapy

Published: July 17, 2021

Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells.

Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells.

Journal: Haematologica

Published: July 22, 2020

Showing 1-12 of 29

Last Updated: 09/26/2026